News

A nurse and PhD candidate with multiple sclerosis (MS) is looking for disease biomarkers that can help healthcare providers better estimate how individual cases of MS will progress. The goal of Stephanie Buxhoeveden’s research, now supported by a grant from the American Association of Nurse Practitioners (AANP), is…

Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to start this year, the RELEASE MSS5…

After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm function worsening in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient. The study, ChariotMS (NCT04695080), aims to…

More than one-third of people with multiple sclerosis (MS) who responded to an online U.S.-based survey are dissatisfied with their quality of life, and more than one in four MS patients are pessimistic about their future, according to the results of the survey, conducted by Multiple Sclerosis News…

Sonoma Biotherapeutics has raised $265 million in investment funding to support the development and production of novel immune T-cell therapies to treat severe autoimmune and inflammatory diseases, such as multiple sclerosis (MS). “We are ushering in a new era of medicine, using immune cells as living therapies that…

Clene’s investigational oral therapy CNM-Au8 improved energy metabolism in the brain of adults with relapsing-remitting multiple sclerosis (RRMS), according to top-line results from the REPAIR-MS trial. This open-label Phase 2 pilot study (NCT03993171), taking place in Texas, is running in parallel with REPAIR-PD, another Phase 2…

High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on treatment, an analysis of placebo-controlled clinical trials shows. However, the therapy failed to improve other measures of disability, and was associated with inaccurate lab test results caused by high levels…

Treatment with the diabetes medication metformin was seen to lessen cognitive impairment, improve coordination, and normalize neuronal activity in a rat model of multiple sclerosis (MS). The study reporting these findings, “Evaluation of the effects of metformin as adenosine monophosphate-activated protein kinase activator on spatial learning and…

Accessing healthcare providers knowledgeable about multiple sclerosis (MS) and being able to afford additional services to improve overall health were the most pressing healthcare concerns among Canadians with the condition, a survey suggests. “These findings provide healthcare planners prioritized concerns and a profile of [people with MS] that have…

A natural, small molecule called 3-HKA) has shown potent anti-inflammatory activity in lab tests and mouse models of immune-related diseases, a study found. The findings suggest that molecules that mimic 3-HKA (3-hydroxy-L-kynurenamine) may serve as broad-acting therapeutics to protect against inflammation in several autoimmune and inflammatory diseases, including multiple…

The low-fat Swank diet and the Wahls elimination diet reduced fatigue and improved quality of life after three months for people with relapsing-remitting multiple sclerosis (RRMS), a clinical trial has found. “It’s encouraging that fatigue was reduced and quality of life improved in both groups,” Bruce Bebo, PhD, from…

Tysabri (natalizumab) given every six weeks was as safe and effective over nearly 1.5 years of use as its approved four-week dosing in people with relapsing-remitting multiple sclerosis (RRMS), according to top-line data from the Phase 3b NOVA study. Tysabri is typically administered every four weeks, or about…

Larger declines with treatment in blood levels of neurofilament light chain (NfL), a marker of nerve cell damage, are associated with fewer brain lesions, less brain shrinkage, and lower relapse rates in people with relapsing forms of multiple sclerosis (MS), a study reported. These results, based on a post-hoc analysis…

The U.S. Food and Drug Administration (FDA) has expanded the label for Botox (onabotulinumtoxinA) in adults for the treatment of upper limb spasticity — a common symptom of multiple sclerosis (MS) — to include eight more muscles. The new approval will allow Botox to be used to treat…

Exposure to multiple sclerosis (MS) disease-modifying therapies (DMTs), and particularly immunosuppressive DMTs, does not increase the risk of developing a severe form of COVID-19, or of dying from the disease, when adjusting for known risk factors, an Austrian registry-based study found. These findings add to data showing no…

“Burgers to Beat MS,” A&W Canada‘s annual fundraiser to support the MS Society of Canada and people with multiple sclerosis (MS), returns for its 13th year on Thursday, Aug. 19, aiming to raise over $1.5 million. Canada has one of the highest MS rates globally, with more than 90,000…

The Administration for Community Living (ACL) reaffirmed its support for the work of the National Paralysis Resource Center (PRC) in aiding people with paralysis — either due to multiple sclerosis (MS), accidents, or other disorders — with a five-year grant. Under a collaborative agreement, the PRC — operated…

People who develop multiple sclerosis (MS) in childhood have more difficulty recognizing words and faces than healthy individuals, a small study found. The volume of certain structures of the limbic system — a part of the brain involved in memory and emotion — is smaller in those with MS,…

Chong Kun Dang (CKD) Pharmaceutical’s experimental oral therapy CKD-506 suppressed inflammation, myelin loss (demyelination), and lessened symptoms in a mouse model of multiple sclerosis (MS), a study reported. Notably, the therapy resulted in benefits generally comparable to those of Gilenya (fingolimod) in these mice. But it also…

A signaling protein called fractalkine helps to regulate the development of oligodendrocytes, cells of the nervous system responsible for making myelin — the protecting coating of nerve cell fibers that is damaged and lost in multiple sclerosis (MS). This finding was in the study, “Fractalkine signaling regulates…

The U.S. Food and Drug Administration (FDA) has given the green light to a Phase 2 clinical trial that will assess the efficacy of using adult mesenchymal stem cells (MSCs) to treat the symptoms of mild to moderate multiple sclerosis (MS). The non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF),…

Subtle changes in structure in the hippocampus — a region of the brain involved in processing memories — can differentiate between relapsing-remitting and primary progressive multiple sclerosis, according to a new study. The study, “Unraveling the MRI-Based Microstructural Signatures Behind Primary Progressive and Relapsing–Remitting Multiple Sclerosis Phenotypes,”…

Removing an ion channel called Piezo1 from immune T-cells lessened disease severity in a mouse model of multiple sclerosis (MS), a study showed. Notably, these beneficial effects were associated with an expansion of regulatory T-cells (Tregs) — a type of immune cell that typically dampens immune and inflammatory responses —…

Tysabri (natalizumab) infusions given in the home to people with relapsing-remitting multiple sclerosis (RRMS) save money and are more convenient, while apparently as safe and effective as those given in clinical settings, a pilot study comparing the two delivery methods reported. Nonetheless, its researchers recommended larger trials be…

People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in their disease in recent years, compared to individuals who switched to the treatment around the time it became available, a new study indicates. The findings suggest “an increased experience in…

Hypertension — high blood pressure — triples the risk of severe walking disability in Hispanic and Latino people with multiple sclerosis (MS), a new observational study reports. The study, “Hypertension and hypertension severity in Hispanics/Latinx with MS,” was published in the Multiple Sclerosis Journal. Although…

Skin reactions are common among relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated in a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use,…

Multivitamin supplements reduce fatigue and improve quality of life in people with relapsing-remitting multiple sclerosis (RRMS), a new study reports. After 70 days of continuous use, patients taking multivitamin supplements containing vitamins A, B-complex, C, and D improved their blood antioxidant status and experienced up to a 34% reduction…

Genetic susceptibility to multiple sclerosis (MS) depends on an individual’s particular combination of multiple risk variants, a study reveals. The study, “Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions,” was published in the journal BMC Medical…

Low doses selected and underlying inflammatory disease may have confounded the ability of temelimab to significantly affect neuroinflammation in a Phase 2 trial in relapsing-remitting multiple sclerosis (RRMS) patients. GeNeuro‘s investigational MS therapy did, however, show other evidence of clinical benefit that supports its continued development, researchers…